HUE057092T2 - Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje - Google Patents

Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje

Info

Publication number
HUE057092T2
HUE057092T2 HUE14812658A HUE14812658A HUE057092T2 HU E057092 T2 HUE057092 T2 HU E057092T2 HU E14812658 A HUE14812658 A HU E14812658A HU E14812658 A HUE14812658 A HU E14812658A HU E057092 T2 HUE057092 T2 HU E057092T2
Authority
HU
Hungary
Prior art keywords
alpha
kinase inhibitor
dosage regimen
isoform selective
selective phosphatidylinositol
Prior art date
Application number
HUE14812658A
Other languages
English (en)
Inventor
Tomaso Emmanuelle Di
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUE057092T2 publication Critical patent/HUE057092T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
HUE14812658A 2013-12-06 2014-12-03 Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje HUE057092T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13306679 2013-12-06

Publications (1)

Publication Number Publication Date
HUE057092T2 true HUE057092T2 (hu) 2022-04-28

Family

ID=49876516

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14812658A HUE057092T2 (hu) 2013-12-06 2014-12-03 Alfa-izoformára szelektív foszfatidilinozitol-3-kináz-inhibitor adagolási rendje

Country Status (23)

Country Link
US (4) US20170000778A1 (hu)
EP (2) EP4000619A1 (hu)
JP (1) JP2016539149A (hu)
KR (1) KR20160095035A (hu)
CN (1) CN105979947A (hu)
AU (2) AU2014358773A1 (hu)
BR (1) BR112016011811A2 (hu)
CA (1) CA2930359C (hu)
CL (1) CL2016001361A1 (hu)
DK (1) DK3076969T3 (hu)
ES (1) ES2899167T3 (hu)
HK (1) HK1223549A1 (hu)
HU (1) HUE057092T2 (hu)
IL (1) IL245709B (hu)
MX (1) MX2016007376A (hu)
PH (1) PH12016501026A1 (hu)
PL (1) PL3076969T3 (hu)
PT (1) PT3076969T (hu)
RU (1) RU2680246C1 (hu)
SI (1) SI3076969T1 (hu)
TN (1) TN2016000179A1 (hu)
TW (1) TWI666019B (hu)
WO (1) WO2015083101A1 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108472289A (zh) * 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2018060833A1 (en) * 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
DE3752123T2 (de) 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
WO1989007105A1 (en) 1988-02-04 1989-08-10 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US6410010B1 (en) 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1993007153A1 (en) 1991-10-10 1993-04-15 Schering Corporation 4'-(n-substituted-n-oxide)staurosporine derivatives
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
JPH07505124A (ja) 1991-11-08 1995-06-08 ザ ユニバーシティ オブ サザン カリフォルニア ニューロトロフィン活性増強のためのｋ−２５２化合物を含む組成物
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
US5948898A (en) 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5621100A (en) 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5756494A (en) 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
ES2225824T3 (es) 1992-08-31 2005-03-16 Ludwig Institute For Cancer Research Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos.
EP0630898B1 (en) 1992-09-21 2001-11-28 Kyowa Hakko Kogyo Co., Ltd. Thrombocytopenia remedy
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
KR100341341B1 (ko) 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 이미다조[4,5-c]피리딘-4-아민
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
ES2236702T3 (es) 1993-12-23 2005-07-16 Eli Lilly And Company Inhibidores de la proteina quinasa c.
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis
FR2741881B1 (fr) 1995-12-01 1999-07-30 Centre Nat Rech Scient Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
JP4301576B2 (ja) 1996-08-02 2009-07-22 ローラス セラピューティクス インコーポレイテッド リボヌクレオチドレダクターゼのｒ１およびｒ２成分に対して指向される抗腫瘍アンチセンス配列
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
EP1017394B1 (en) 1997-07-12 2005-12-07 Cancer Research Technology Limited Cyclin dependent kinase inhibiting purine derivatives
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
TR200003514T2 (tr) 1998-05-29 2002-05-21 Sugen Inc. Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri
US20030083242A1 (en) 1998-11-06 2003-05-01 Alphonse Galdes Methods and compositions for treating or preventing peripheral neuropathies
EP1189641B1 (en) 1999-06-25 2009-07-29 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
EP1201668A4 (en) 1999-07-13 2003-05-21 Kyowa Hakko Kogyo Kk STAUROSPORINE DERIVATIVES
NZ518028A (en) 1999-11-05 2004-03-26 Astrazeneca Ab Quinazoline derivatives as VEGF inhibitors
WO2001039763A2 (en) * 1999-12-06 2001-06-07 Rhode Island Hospital, A Lifespan Partner Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors
ME00415B (me) 2000-02-15 2011-10-10 Pharmacia & Upjohn Co Llc Pirol supstituisani 2-indol protein kinazni inhibitori
AU2001253427B2 (en) 2000-04-12 2007-02-08 Genaera Corporation A process for the preparation of 7.alpha.-hydroxy 3-aminosubstituted sterols using intermediates with an unprotected 7.alpha.-hydroxy group
DE60126611T2 (de) 2000-06-30 2007-11-22 Glaxo Group Ltd., Greenford Ditosylatsalze von chinazolinverbindungen
US6605617B2 (en) 2000-09-11 2003-08-12 Chiron Corporation Quinolinone derivatives
US6677450B2 (en) 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
WO2002057423A2 (en) 2001-01-16 2002-07-25 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
WO2002062826A1 (fr) 2001-02-07 2002-08-15 Vadim Viktorovich Novikov Procede de fabrication des peptides
US20040186172A1 (en) 2001-07-02 2004-09-23 Houssam Ibrahim Oxaliplatin active substance with a very low content of oxalic acid
KR100484504B1 (ko) 2001-09-18 2005-04-20 학교법인 포항공과대학교 쿠커비투릴 유도체를 주인 분자로서 포함하고 있는 내포화합물 및 이를 포함한 약제학적 조성물
US20030134846A1 (en) 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
AU2003226211B2 (en) 2002-03-29 2008-05-29 Novartis Vaccines And Diagnostics, Inc. Substituted benzazoles and use thereof as RAF kinase inhibitors
US6727272B1 (en) 2002-07-15 2004-04-27 Unitech Pharmaceuticals, Inc. Leflunomide analogs for treating rheumatoid arthritis
US7148342B2 (en) 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
WO2004060308A2 (en) 2002-12-27 2004-07-22 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
WO2004064759A2 (en) 2003-01-21 2004-08-05 Chiron Corporation Use of tryptanthrin compounds for immune potentiation
US7893096B2 (en) 2003-03-28 2011-02-22 Novartis Vaccines And Diagnostics, Inc. Use of small molecule compounds for immunopotentiation
PL1853250T3 (pl) * 2005-02-18 2012-03-30 Abraxis Bioscience Llc Kombinacje i sposoby podawania środków terapeutycznych oraz terapia skojarzona
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
MX360157B (es) * 2010-11-08 2018-10-24 Novartis Ag Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
CN103619840B (zh) * 2011-06-21 2016-01-20 诺华股份有限公司 (s)-吡咯烷-1,2-二羧酸2-酰胺1-{4-甲基-5-[2-(2,2,2-三氟-1,1-二甲基-乙基)-吡啶-4-基]噻唑-2-基}酰胺的多晶型物
EP2601965A1 (en) * 2011-12-06 2013-06-12 Apeiron Biologics AG Compositions for preventing or treating adverse reactions of EGFR inhibition
US10213432B2 (en) * 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor

Also Published As

Publication number Publication date
PT3076969T (pt) 2021-11-23
SI3076969T1 (sl) 2021-12-31
DK3076969T3 (da) 2021-11-22
EP3076969B1 (en) 2021-09-01
AU2017245292B2 (en) 2018-09-27
CA2930359C (en) 2022-03-01
AU2014358773A1 (en) 2016-06-02
US20180078540A1 (en) 2018-03-22
TN2016000179A1 (en) 2017-10-06
ES2899167T3 (es) 2022-03-10
US20210196696A1 (en) 2021-07-01
WO2015083101A1 (en) 2015-06-11
TW201609096A (zh) 2016-03-16
CN105979947A (zh) 2016-09-28
EP3076969A1 (en) 2016-10-12
HK1223549A1 (zh) 2017-08-04
IL245709A0 (en) 2016-07-31
KR20160095035A (ko) 2016-08-10
CA2930359A1 (en) 2015-06-11
BR112016011811A2 (pt) 2017-08-08
RU2680246C1 (ru) 2019-02-19
US10434092B2 (en) 2019-10-08
CL2016001361A1 (es) 2017-02-10
AU2017245292A1 (en) 2017-11-02
PH12016501026A1 (en) 2016-07-04
PL3076969T3 (pl) 2022-01-17
TWI666019B (zh) 2019-07-21
US20170000778A1 (en) 2017-01-05
US20200069670A1 (en) 2020-03-05
MX2016007376A (es) 2017-05-11
JP2016539149A (ja) 2016-12-15
EP4000619A1 (en) 2022-05-25
IL245709B (en) 2021-03-25

Similar Documents

Publication Publication Date Title
HK1223911A1 (zh) 磷脂醯肌醇 -激酶抑制劑
HK1224296A1 (zh) 布羅莫結構域抑制劑
IL241123A0 (en) Dihydro-pyrrolopyridinones as inhibitors of bromo sites
HUE060767T2 (hu) Brómdomén inhibitorok
HK1220459A1 (zh) 激酶抑制劑
EP2948458A4 (en) BTK INHIBITORS
EP2948431A4 (en) BTK INHIBITORS
HK1219104A1 (zh) 激酶抑制劑
HK1224281A1 (zh) 磷脂酰肌醇 -激酶抑制劑的製備方法
IL242803A0 (en) Dihydropyridinones as mgat2 inhibitors
SG11201509650YA (en) Slc2a transporter inhibitors
IL245737A0 (en) Glucosylceramide synthase inhibitors
SG11201502929SA (en) Quorum sensing inhibitors
HK1252411A1 (zh) 磷脂酰肌醇3-激酶抑制劑的給藥方案
IL245709A0 (en) Dosage regimen for a selective inhibitor of the alpha isoform of phosphatidylinositol 3-kinase
EP2968458A4 (en) DOSAGE SCHEME FOR THERAPEUTIC PROCESS
PL3068829T3 (pl) Plastyfikatory do polimerów
HUP1300593A2 (en) Optoelektronic device for detecting small objects
GB201307155D0 (en) Kinase inhibitors